03/02/2017
Auris Medical Expands Clinical Development Pipeline with Intranasal Betahistine for the Treatment of Meniere's Disease and Vestibular Vertigo
Auris Medical Holding AG(NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has added a third clinical-stage development program [....]
